907 related articles for article (PubMed ID: 17692726)
41. Bisphosphonates for post-menopausal osteoporosis: are they all the same?
Rizzoli R
QJM; 2011 Apr; 104(4):281-300. PubMed ID: 21258058
[TBL] [Abstract][Full Text] [Related]
42. [Non-hormonal treatments of postmenopausal osteoporosis].
Malaise O; Neuprez A; Reginster JY
Gynecol Obstet Fertil; 2008; 36(7-8):815-22. PubMed ID: 18653373
[TBL] [Abstract][Full Text] [Related]
43. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
Grazio S; Morović-Vergles J
Reumatizam; 2007; 54(2):89-92. PubMed ID: 18351154
[TBL] [Abstract][Full Text] [Related]
44. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
[TBL] [Abstract][Full Text] [Related]
45. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
Jansen JP; Bergman GJ; Huels J; Olson M
Curr Med Res Opin; 2009 Aug; 25(8):1861-8. PubMed ID: 19530978
[TBL] [Abstract][Full Text] [Related]
46. Factors contributing to compliance with osteoporosis medication.
Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
[TBL] [Abstract][Full Text] [Related]
48. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
Payer J; Killinger Z; Sulková I; Celec P
Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
[TBL] [Abstract][Full Text] [Related]
49. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
50. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
51. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
52. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
53. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
54. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
55. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.
Recker RR; Gallagher R; MacCosbe PE
Mayo Clin Proc; 2005 Jul; 80(7):856-61. PubMed ID: 16007889
[TBL] [Abstract][Full Text] [Related]
56. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
Ilter E; Karalok H; Tufekci EC; Batur O
Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
[TBL] [Abstract][Full Text] [Related]
58. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
59. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
60. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
